Popper SJ - Search Results

1

Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2.

Popper SJ, Sarr AD, Travers KU, Guèye-Ndiaye A, Mboup S, Essex ME, Kanki PJ. Popper SJ, et al. J Infect Dis. 1999 Oct;180(4):1116-21. doi: 10.1086/315010. J Infect Dis. 1999. PMID: 10479138

2

The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection.

Rodriguez SK, Sarr AD, Olorunnipa O, Popper SJ, Gueye-Ndiaye A, Traoré I, Dia MC, Mboup S, Kanki PJ. Rodriguez SK, et al. Among authors: popper sj. J Infect Dis. 2006 Sep 15;194(6):760-3. doi: 10.1086/507042. Epub 2006 Aug 17. J Infect Dis. 2006. PMID: 16941341

3

Associations between MHC class I and susceptibility to HIV-2 disease progression.

Diouf K, Sarr AD, Eisen G, Popper S, Mboup S, Kanki P. Diouf K, et al. J Hum Virol. 2002 Jan-Feb;5(1):1-7. J Hum Virol. 2002. PMID: 12352262

4

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

Mullins C, Eisen G, Popper S, Dieng Sarr A, Sankale JL, Berger JJ, Wright SB, Chang HR, Coste G, Cooley TP, Rice P, Skolnik PR, Sullivan M, Kanki PJ. Mullins C, et al. Clin Infect Dis. 2004 Jun 15;38(12):1771-9. doi: 10.1086/421390. Epub 2004 May 25. Clin Infect Dis. 2004. PMID: 15227626

5

Relation between HIV-2 proviral load and CD4+ lymphocyte count differs in monotypic and dual HIV infections.

Sarr AD, Popper S, Thior I, Hamel DJ, Sankalé JL, Siby T, Marlink R, Essex M, Mboup S, Kanki P. Sarr AD, et al. J Hum Virol. 1999 Jan-Feb;2(1):45-51. J Hum Virol. 1999. PMID: 10200599

6

Antibodies to the HIV type 2 core protein p26 and Vpx: association with disease progression.

Popper SJ, Sankalé JL, Thior I, Siby T, Marlink RG, Mboup S, Essex M, Kanki PJ. Popper SJ, et al. AIDS Res Hum Retroviruses. 1998 Sep 1;14(13):1157-62. doi: 10.1089/aid.1998.14.1157. AIDS Res Hum Retroviruses. 1998. PMID: 9737587

7

Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo.

Popper SJ, Sarr AD, Guèye-Ndiaye A, Mboup S, Essex ME, Kanki PJ. Popper SJ, et al. J Virol. 2000 Feb;74(3):1554-7. doi: 10.1128/jvi.74.3.1554-1557.2000. J Virol. 2000. PMID: 10627569 Free PMC article.

8

Robust HIV type 2 cellular immune response measured by a modified anthrax toxin-based enzyme-linked immunospot assay.

Sarr AD, Lu Y, Sankalé JL, Eisen G, Popper S, Mboup S, Kanki PJ, Cao H. Sarr AD, et al. AIDS Res Hum Retroviruses. 2001 Sep 1;17(13):1257-64. doi: 10.1089/088922201750461311. AIDS Res Hum Retroviruses. 2001. PMID: 11559425

9

Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals.

Dieye TN, Sow PS, Simonart T, Guèye-Ndiaye A, Popper SJ, Delforge ML, Dieye A, Sarr AD, Crusiaux A, Van Vooren JP, Devleeschouwer M, Kanki P, Mboup S, Diakhate L, Farber CM. Dieye TN, et al. Among authors: popper sj. Vaccine. 2001 Dec 12;20(5-6):905-13. doi: 10.1016/s0264-410x(01)00383-8. Vaccine. 2001. PMID: 11738756

10

Gene transcript abundance profiles distinguish Kawasaki disease from adenovirus infection.

Popper SJ, Watson VE, Shimizu C, Kanegaye JT, Burns JC, Relman DA. Popper SJ, et al. J Infect Dis. 2009 Aug 15;200(4):657-66. doi: 10.1086/603538. J Infect Dis. 2009. PMID: 19583510 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters